Market Overview

Bank of America Initiates Coverage on Jazz Pharmaceuticals Positive Outlook

Related JAZZ
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1
Jazz Pharma, Concert Pharma Report JZP-386 Program Update
IBD 50 Turns In Solid Week As Market Uptrend Resumes (Investor's Business Daily)

In a report published Monday, Bank of America initiated coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and $74 price objective.

Bank of America reported that, “We initiated coverage of Jazz with a Buy rating and $74 PO, which is based on a sum-of-the-parts DCF analysis and does not require multiple expansion. We like Jazz's focus on areas with strong growth potential and franchise durability, and we expect strong sales and EPS growth over the next several years driven by Xyrem and Erwinaze.”

Jazz Pharmaceuticals closed at $56.03 on Monday.

Latest Ratings for JAZZ

Nov 2014CitigroupMaintainsBuy
Nov 2014Stifel NicolausMaintainsBuy
Aug 2014JP MorganInitiates Coverage onOverweight

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Analyst Ratings


Related Articles (JAZZ)

Around the Web, We're Loving...

Get Benzinga's Newsletters